Literature DB >> 20553816

Glycogen synthase kinase-3 regulates inflammatory tolerance in astrocytes.

E Beurel1, R S Jope.   

Abstract

Inflammatory tolerance is the down-regulation of inflammation upon repeated stimuli, which is well-established to occur in peripheral immune cells. However, less is known about inflammatory tolerance in the brain although it may provide an important protective mechanism from detrimental consequences of prolonged inflammation, which appears to occur in many psychiatric and neurodegenerative conditions. Array analysis of 308 inflammatory molecules produced by mouse primary astrocytes after two sequential stimulations with lipopolysaccharide (LPS) distinguished three classes, tolerant, sensitized and unaltered groups. For many of these inflammatory molecules, inhibition of glycogen synthase kinase-3 (GSK3) increased tolerance and reduced sensitization. Focusing on LPS-tolerance in interleukin-6 (IL-6) production, we found that microglia exhibited a strong tolerance response that matched that of macrophages, whereas astrocytes exhibited only partial tolerance. The astrocyte semi-tolerance was found to be regulated by GSK3. GSK3 inhibitors or knocking down GSK3 levels promoted LPS-tolerance and astrocytes expressing constitutively active GSK3 did not develop LPS-tolerance. These findings identify the critical role of GSK3 in counteracting IL-6 inflammatory tolerance in cells of the CNS, supporting the therapeutic potential of GSK3 inhibitors to reduce neuroinflammation by promoting tolerance. Copyright (c) 2010 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20553816      PMCID: PMC2914115          DOI: 10.1016/j.neuroscience.2010.05.044

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  38 in total

Review 1.  The renaissance of GSK3.

Authors:  P Cohen; S Frame
Journal:  Nat Rev Mol Cell Biol       Date:  2001-10       Impact factor: 94.444

2.  Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25.

Authors:  M Leost; C Schultz; A Link; Y Z Wu; J Biernat; E M Mandelkow; J A Bibb; G L Snyder; P Greengard; D W Zaharevitz; R Gussio; A M Senderowicz; E A Sausville; C Kunick; L Meijer
Journal:  Eur J Biochem       Date:  2000-10

Review 3.  GSK-3: tricks of the trade for a multi-tasking kinase.

Authors:  Bradley W Doble; James R Woodgett
Journal:  J Cell Sci       Date:  2003-04-01       Impact factor: 5.285

Review 4.  The glamour and gloom of glycogen synthase kinase-3.

Authors:  Richard S Jope; Gail V W Johnson
Journal:  Trends Biochem Sci       Date:  2004-02       Impact factor: 13.807

5.  Inhibition of lipopolysaccharide-induced signal transduction in endotoxin-tolerized mouse macrophages: dysregulation of cytokine, chemokine, and toll-like receptor 2 and 4 gene expression.

Authors:  A E Medvedev; K M Kopydlowski; S N Vogel
Journal:  J Immunol       Date:  2000-06-01       Impact factor: 5.422

6.  First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease.

Authors:  Ana Martinez; Mercedes Alonso; Ana Castro; Concepción Pérez; Francisco J Moreno
Journal:  J Med Chem       Date:  2002-03-14       Impact factor: 7.446

7.  Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation.

Authors:  K P Hoeflich; J Luo; E A Rubie; M S Tsao; O Jin; J R Woodgett
Journal:  Nature       Date:  2000-07-06       Impact factor: 49.962

8.  Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment.

Authors:  S J Bull; P Huezo-Diaz; E B Binder; J F Cubells; G Ranjith; C Maddock; C Miyazaki; N Alexander; M Hotopf; A J Cleare; S Norris; E Cassidy; K J Aitchison; A H Miller; C M Pariante
Journal:  Mol Psychiatry       Date:  2008-05-06       Impact factor: 15.992

Review 9.  Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes.

Authors:  Allan S Wagman; Kirk W Johnson; Dirksen E Bussiere
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

10.  Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue.

Authors:  K D McCarthy; J de Vellis
Journal:  J Cell Biol       Date:  1980-06       Impact factor: 10.539

View more
  23 in total

Review 1.  New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors.

Authors:  Michael Maes; Zdenĕk Fišar; Miguel Medina; Giovanni Scapagnini; Gabriel Nowak; Michael Berk
Journal:  Inflammopharmacology       Date:  2012-01-24       Impact factor: 4.473

Review 2.  Crosstalk between insulin and Toll-like receptor signaling pathways in the central nervous system.

Authors:  Fatemeh Hemmati; Rasoul Ghasemi; Norlinah Mohamed Ibrahim; Leila Dargahi; Zahurin Mohamed; Azman Ali Raymond; Abolhassan Ahmadiani
Journal:  Mol Neurobiol       Date:  2014-01-25       Impact factor: 5.590

3.  Increased GSK-3β expression in DRG microglia in response to sciatic nerve crush.

Authors:  Wenjie Tang; Bing Li; Sheng Chen; Ying Lu; Ning Han; Xia Li; Zengchun Li; Youzhen Wei
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2016-04-28       Impact factor: 3.848

4.  Cyanidin attenuates Aβ25-35-induced neuroinflammation by suppressing NF-κB activity downstream of TLR4/NOX4 in human neuroblastoma cells.

Authors:  Sarinthorn Thummayot; Chainarong Tocharus; Pichaya Jumnongprakhon; Apichart Suksamrarn; Jiraporn Tocharus
Journal:  Acta Pharmacol Sin       Date:  2018-04-19       Impact factor: 6.150

Review 5.  Molecular Pathways: Revisiting Glycogen Synthase Kinase-3β as a Target for the Treatment of Cancer.

Authors:  Amy Walz; Andrey Ugolkov; Sunandana Chandra; Alan Kozikowski; Benedito A Carneiro; Thomas V O'Halloran; Francis J Giles; Daniel D Billadeau; Andrew P Mazar
Journal:  Clin Cancer Res       Date:  2017-01-04       Impact factor: 12.531

6.  Neurons and astroglia govern microglial endotoxin tolerance through macrophage colony-stimulating factor receptor-mediated ERK1/2 signals.

Authors:  Chun-Hsien Chu; Shijun Wang; Chia-Ling Li; Shih-Heng Chen; Chih-Fen Hu; Yi-Lun Chung; Shiou-Lan Chen; Qingshan Wang; Ru-Band Lu; Hui-Ming Gao; Jau-Shyong Hong
Journal:  Brain Behav Immun       Date:  2016-04-27       Impact factor: 7.217

7.  Dihydromyricetin exerts a rapid antidepressant-like effect in association with enhancement of BDNF expression and inhibition of neuroinflammation.

Authors:  Zhaoxiang Ren; Pengju Yan; Liushuai Zhu; Huicui Yang; Yafei Zhao; Brian P Kirby; John L Waddington; Xuechu Zhen
Journal:  Psychopharmacology (Berl)       Date:  2017-10-20       Impact factor: 4.530

8.  GSK-3β Governs Inflammation-Induced NFATc2 Signaling Hubs to Promote Pancreatic Cancer Progression.

Authors:  Sandra Baumgart; Nai-Ming Chen; Jin-San Zhang; Daniel D Billadeau; Irina N Gaisina; Alan P Kozikowski; Shiv K Singh; Daniel Fink; Philipp Ströbel; Caroline Klindt; Lizhi Zhang; William R Bamlet; Alexander Koenig; Elisabeth Hessmann; Thomas M Gress; Volker Ellenrieder; Albrecht Neesse
Journal:  Mol Cancer Ther       Date:  2016-01-28       Impact factor: 6.261

9.  Glycogen synthase kinase-3β: a mediator of inflammation in Alzheimer's disease?

Authors:  Jari Koistinaho; Tarja Malm; Gundars Goldsteins
Journal:  Int J Alzheimers Dis       Date:  2011-05-04

10.  Regulation by glycogen synthase kinase-3 of inflammation and T cells in CNS diseases.

Authors:  Eléonore Beurel
Journal:  Front Mol Neurosci       Date:  2011-08-31       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.